Minneapolis, MN, United States
Minneapolis, MN, United States

Time filter

Source Type

Patent
Bio-Techne | Date: 2015-09-08

The disclosed methods involve deglycosylating a target molecule to remove target carbohydrates to create vacant glycosylation acceptor sites and then using glycosyltransferases to incorporate replacement carbohydrates into those sites. The methods also involve using glycosytransferases to incorporate new carbohydrates into vacant glycosylation acceptor sites without having to perform in vitro deglycosylation. The replacement or new carbohydrates include a click chemistry moiety that reacts to a click chemistry moiety on a label.


The disclosure relates to in vitro methods of detecting presence or absence of a target carbohydrate on a glycoprotein. The disclosure also relates to in vitro methods of detecting presence or absence of a glycan epitope on a glycoprotein.


— The report "Western Blotting Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease Diagnostics), End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies) - Global Forecasts to 2021", This report studies the global western blotting market for the forecast period of 2016 to 2021. This market is expected to reach USD 730.7 Million by 2021 from USD 574.8 Million in 2016, growing at a CAGR of 4.9 %. The global western blotting market is segmented on the basis of product, application, end user and region. By product, the western blotting market is categorized into consumables and instruments. The consumables segment is expected to command the largest share of the global western blotting market, by product in 2016. This is attributed to factors such as increasing use of western blotting in research & diagnosis and rising incidence of diseases that require western blotting for diagnosis. The western blotting instruments are further segmented into gel electrophoresis instruments, blotting systems, and imagers. The blotting systems segment is expected to account for the largest share of the western blotting instruments market, by type in 2016. The semi-dry blotting systems are expected to command the largest share of blotting systems market, by type and are likely to grow at the highest CAGR during the forecast period. The largest share of this segment is attributed to high sensitivity, low run time, and high efficiency. On the basis of application, the global western blotting market is segmented biomedical & biochemical research, disease diagnostics, agriculture and others (biologics and quality control). The biomedical & biochemical research segment is expected to account for the largest share of the global western blotting market, by application in 2016. This can be attributed to the rising government spending in proteomics research, and increased R&D spending by pharmaceutical & biotechnology companies in drug discovery and development. However, the disease diagnostics segment is projected to grow at the highest CAGR from 2016 to 2021. This can be attributed rising prevalence and incidences of HIV, HSV, HBV, and Lyme disease, among others. On the basis of end user, the western blotting market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, diagnostic centers and others (CROs, food & beverage companies and forensic laboratories). In 2016, the academic & research institutes segment is expected to command the largest share of the global western blotting market, by end user. This can be attributed to the increasing research activities in the academic institutes backed by government funding and HIV initiatives by various governments across the globe. However, the disease diagnostics segment is projected to grow at the highest CAGR from 2016 to 2021. On the basis of region, the global market is divided into North America, Europe, Asia-Pacific, and the Rest of the World. In 2016, North America is poised to account for the largest share of the western blotting market, followed by Europe and Asia-Pacific. However, the Asia-Pacific market is slated to grow at the highest CAGR during the forecast period. Factors such as development of bioclusters in China and India, growing pharmaceutical and biotechnology sector in Japan, growing funding for agriculture research in India, increasing government interest in biomedical & biotechnology industry in China, increasing diagnosis and related funding for HIV in Australia, and growing prevalence of HSV in south east Asia are expected to propel the growth of the western blotting market in the Asia-Pacific region. Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), GE Healthcare (U.S.), Advansta, Inc. (U.S.), LI-COR Biosciences (U.S.), PerkinElmer, Inc. (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), and Cell Signaling Technology, Inc. (U.S.) are some of the key players in the western blotting market worldwide. For more information, please visit http://www.marketsandmarkets.com/pdfdownload.asp?id=235810711


News Article | October 31, 2016
Site: www.prnewswire.com

MINNEAPOLIS, Oct. 31, 2016 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2016. First Quarter FY2017 Highlights First quarter organic revenue increased by 10% (16% reported) to $130.6...


News Article | December 14, 2016
Site: www.prnewswire.com

MINNEAPOLIS and SAN DIEGO, Dec. 14, 2016 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today closed on a strategic equity investment in Astute Medical, Inc. (San Diego, CA), a diagnostic company devoted to improving patient healthcare outcomes through the identification and...


* Aperio RNA ISH Algorithm and BOND RX are for Research Use Only. Not for use in diagnostic procedures. Leica Biosystems and Advanced Cell Diagnostics (ACD) - a Bio-Techne brand, proudly announce the availability of the Aperio RNA ISH Algorithm for use with ACD's RNAscope ISH assays. This offering builds on the existing collaboration between the two companies to automate ACD's RNAscope assays on the Leica Biosystems BOND RX research staining platform. The Leica Biosystems new RNA ISH Algorithm completes the automated RNA ISH workflow for researchers performing the RNAscope assay on the BOND RX. RNA in-situ hybridization (ISH) is a powerful molecular technique. ACD's RNAscope assays provide robust single RNA molecule detection for formalin-fixed, paraffin-embedded (FFPE) tissue. These assays have been adopted across the globe by major pharma biotech companies, and leading research institutions at more than 3000 labs. However, manual RNA ISH interpretation is time-consuming, subject to inter- and intra-observer variability, and typically only semi-quantitative. The Aperio RNA ISH Algorithm enables accurate identification and standardized quantification of individual signals and clusters on single- or dual-plex stained slides.  Now, researchers using the Leica Biosystems BOND RX  can seamlessly generate quantitative results using the Aperio image analysis software. "The new Aperio RNA ISH Algorithm from our innovation partner, Leica Biosystems, is a welcome addition to our RNAscope data analysis tool set, providing expanded options for our customers pursuing diverse analyses in academic research, drug development and clinical research, said Chris Silva, Vice President of Marketing at ACD.  "With our expanding list of applications in immune-oncology, inflammation, neuroscience and infectious disease, flexibility in generating various quantitative analysis further enables our customers to make enhanced interpretation of what is visualized." Marlon Thompson, Vice President, Image Analysis and Clinical Solutions at Leica Biosystems added, "Leica Biosystems is excited to expand on the existing partnership with ACD by providing high-end image analysis capabilities that complements a complete solution from assay to results. Customers can leverage an automated assay and the underlying power of digital pathology to more easily attain accurate, standardized and reproducible results." Learn more about the ACD and LBS solution for RNA ISH in the upcoming live webinar on Dec 1st 2016: "RNA ISH - Automated Solutions for Better Research." Register here.


News Article | March 1, 2017
Site: www.prnewswire.com

MINNEAPOLIS, March 1, 2017 /PRNewswire/ -- Bio-Techne Corporation has partnered with Brazil-based DK Diagnostics to release its first diagnostic tool for the veterinary market. The PARATEST system is an innovative parasitological system which contains the only non-toxic, biodegradable...


News Article | November 15, 2016
Site: www.newsmaker.com.au

The term ‘Glycobiology’ was first introduced by Rademacher et al., in 1988, incorporating a varied array of molecules, collectively termed as ‘glycoconjugates’. Glycobiology is a branch of ‘Glycosciences’. Glycoscience is interdisciplinary stream having two branches viz. glycochemistry and glycobiology, which require the involvement of researchers in various disciplines including but not limited to medical science, pharmaceutical science, microbiology, biochemistry, material science, and biotechnology. Extensive research related to carbohydrate molecule in various fields such as marine science and food & beverages industry is expected to fuel growth of the global glycobiology market. The global market is expected to reach a value of US$ 1,670.3 Mn by 2024, registering a CAGR of 12.8% between 2016 and 2024, according to a new report by Persistence Market Research (PMR). PMR’s report offers market forecast and analysis on the global glycobiology market, while segmenting the market on the basis of product-type, application, end-user, and region. The report segments the global glycobiology market into five key regions: North America, Latin America, Europe, Middle East and Africa (MEA), and Asia Pacific (APAC). According to PMR regional analysis, North America (including the U.S. and Canada) is the most lucrative market for glycobiology globally. This region is expected to account for highest market share over the forecast period (2016–2024) and is expected to exhibit a significantly high growth rate. Asia Pacific is expected to be the fastest growing market in the global glycobiology market owing to increasing awareness amongst researchers regarding the various benefits of research related to carbohydrate molecules and its association with novel drug development. APAC is estimated to account for around 19.1% revenue share in the global glycobiology market by the end of 2016. MEA region is also expected to register significant growth over the forecast period owing to increasing R&D expenditure by pharmaceutical industries. This region is expected to register a CAGR of 11.0% over the forecast period. On the basis of product type, PMR has segmented the glycobiology market into instruments, enzymes, consumables and reagent kits segments. Enzymes product type segment is expected to dominate the market through the forecast period and is anticipated to be the most lucrative segment. Enzyme product type segment accounted for 52.6% revenue share in 2015. Due to high adoption rate of enzymes to conduct various research initiatives, this segment is expected to witness high incremental opportunity globally. On the basis of application, PMR has segmented the glycobiology market into drug discovery and development, therapeutic application, diagnostic application, industrial application, and others segments. Drug discovery and development application segment is expected to dominate the market and is anticipated to be the most lucrative segment growing at a CAGR of 13.4% over the forecast period. On the basis of end user, the glycobiology market has been segmented into biopharmaceutical companies, research laboratories, hospitals, diagnostic centers, contract research organization, biotechnology industry, academic institutes, and others. PMR estimates that biopharmaceutical companies end user segment is expected to account for highest revenue share in the global glycobiology market and is expected to witness fastest growth over the forecast period. Factors such as increasing demand for novel drug development, especially for chronic diseases such as cancer and diabetes, is expected to boost revenue share contribution from the biopharmaceutical companies segment. Research laboratories segment is also expected to register a significant growth rate during the forecast period. Some key market participants included in PMR’s global glycobiology market report include Merck KGaA, Bio-Techne Corporation, Bruker Corporation, Thermo Fisher Scientific, Inc., Shimadzu Corporation, Plexera Bioscience LLC, New England Biolabs Inc., Agilent Technologies, Inc., and ProZyme, Inc.


Stem Cells Cryopreservation Equipments Market analysis is provided for global market including development trends by regions, competitive analysis of the Stem Cells Cryopreservation Equipments market. Stem Cells Cryopreservation Equipments Industry report focuses on the major drivers and restraints for the key players. Stem Cells Cryopreservation Equipment (SCCE) is medical equipment used in the freezing and storage for stem cells. Cryopreservation is the use of low temperatures to preserve structurally intact living stem cells. Stem Cells Cryopreservation Equipments market analysis report speaks about the manufacturing process. The process is analysed thoroughly with respect four points Manufacturers, regional analysis, Segment by Type and Segment by Applications and the actual process of whole Stem Cells Cryopreservation Equipments industry. And many more This report focuses on the Stem Cells Cryopreservation Equipments in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Market Segment by Applications, can be divided into Have Any Query? Ask Our Expert for Stem Cells Cryopreservation Equipments Market Report @ http://www.marketreportsworld.com/enquiry/pre-order-enquiry/10292648 Chapter 8: South America, Middle East and Africa Stem Cells Cryopreservation Equipments Sales, Revenue and Market Share by Countries Another related report is “Global Mesenchymal Stem Cells Market by Manufacturers, Regions, Type and Application, Forecast to 2021”, this report focuses on the Report Market in Global market, especially in North America, Europe and Asia-Pacific, Latin America, Middle and Africa. This report categorizes the market based on manufacturers, regions, type and application. Market Segment by Manufacturers, this report covers are Lonza, Thermo Fisher, Bio-Techne, Miltenyi Biotec, PromoCell GmbH and others Market Segment by Applications, can be divided into Cell Differentiation and Gene Regulation, Gene Therapy and Transplantation, Cell-based Screening Assays and Others. Comprehensive table of Content is available at http://www.marketreportsworld.com/10289481 Market Reports World is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.


News Article | February 15, 2017
Site: marketersmedia.com

LONDON, UK / ACCESSWIRE / February 14, 2017 / Active Wall St. blog coverage looks at the headline from Inovio Pharmaceuticals, Inc. (NASDAQ: INO) as the Company announced on February 13, 2017, Inovio Pharma announced that it has entered into a collaboration and licens eagreement with Chinese biomedical firm ApolloBio Corporation. The agreement grants ApolloBio the exclusive right to develop and commercialize VGX-3100, Inovio's DNA immunotherapy product designed to treat pre-cancers caused by human papillomavirus (HPV), within Greater China market comprising of China, Hong Kong, Macao, and Taiwan. The agreement also provisions for potential inclusion of the Republic of Korea three years following the effective date. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/. One of Inovio Pharma's competitors within the Biotechnology space, Bio-Techne Corp. (NASDAQ: TECH), reported on February 07, 2017, its financial results Q2 ended December 31, 2016. AWS will be initiating a research report on Bio-Techne in the coming days. Today, AWS is promoting its blog coverage on INO; touching on TECH. Get all of our free blog coverage and more by clicking on the links below: http://www.activewallst.com/register/. As per terms of the agreement, Inovio will receive $15 million in upfront and near-term payments comprising an initial $3 million signing fee and a $12 million milestone upon lifting of the VGX-3100 phase-3 pre-initiation clinical hold by the FDA since October 2016. ApolloBio will fund all clinical development costs within the licensed territory, and will pay Inovio up to $20 million based upon the achievement of certain regulatory milestones in the US, China, and Korea, and double digit royalties on net sales of VGX-3100. Under a separate equity agreement, ApolloBio will invest in Inovio's common stock, once the hold on clinical trial is lifted at a volume weighted average price encompassing a trading period prior to and following the lifting of the clinical hold. Inovio stated that the investment will not exceed $35 million and is structured in a way that the amount may be lowered in order to ensure that ApolloBio will not be the largest shareholder in Inovio. The agreements are subject to People's Republic of China (PRC) corporate and regulatory approvals and payments are subject to PRC's currency approvals. This collaboration on VGX-3100 encompasses the treatment and/or prevention of pre-cancerous HPV infections and HPV-driven dysplasias, and excludes HPV-driven cancers and all combinations of VGX-3100 with other immunostimulants. Dr. J. Joseph Kim, Inovio's President and Chief Executive Officer, said: "As Inovio continues to focus on the path to regulatory approvals and commercialization strategies in the US and European countries, this agreement opens up Greater China for our lead program and first phase-III product. We believe that ApolloBio is a strong partner that brings significant capabilities and expertise relating to product development, the Chinese regulatory landscape, and the healthcare market in China." Inovio's VGX-3100 is an HPV-specific immunotherapy that is being developed as a non-surgical treatment for high-grade cervical dysplasia and related underlying persistent HPV infection. VGX-3100 works in vivo to activate functional, antigen-specific, CD-8 T-cells to clear persistent HPV 16/18 infection and cause regression of pre-cancerous cervical dysplasia. In a phase-II trial, VGX-3100 demonstrated clinical efficacy and was generally well tolerated, without the side effects and obstetric risks associated with surgical excision. VGX-3100 is a first-in-class HPV-specific immunotherapy that targets the underlying cause of cervical dysplasia, providing an opportunity for women to reduce their risk of cervical cancer without undergoing an invasive surgical procedure. As per the official press release, HPV is the most common sexually transmitted infection and is the main cause of cervical cancer, which kills more than 250,000 women every year worldwide. Among the 300 million women currently infected with HPV, 500,000 will be diagnosed with cervical cancer each year. Two types of HPV (HPV 16 and HPV 18) cause 70% of cervical cancer cases. High-grade cervical dysplasia is also caused by persistent HPV infection and is a pre-cancerous condition that can progress to cervical cancer if left untreated. Globally, the number of high-grade cervical dysplasia cases is estimated to be in the range of 10 million. Inovio stated that there are currently no approved medical treatments for persistent HPV infection or cervical dysplasia. The primary treatment for high-grade cervical dysplasia is surgical excision of the pre-cancerous lesion and a margin of healthy cervical tissue. At the close of trading session on Monday, February 13, following the announcement, Inovio Pharma's stock price jumped 6.57% to end the day at $6.81. A total volume of 1.46 million shares were exchanged during the session, which was above the 3-month average volume of 895.38 thousand shares. The Company's share price has gained 8.61% in the past twelve months. The stock currently has a market cap of $513.07 million. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / February 14, 2017 / Active Wall St. blog coverage looks at the headline from Inovio Pharmaceuticals, Inc. (NASDAQ: INO) as the Company announced on February 13, 2017, Inovio Pharma announced that it has entered into a collaboration and licens eagreement with Chinese biomedical firm ApolloBio Corporation. The agreement grants ApolloBio the exclusive right to develop and commercialize VGX-3100, Inovio's DNA immunotherapy product designed to treat pre-cancers caused by human papillomavirus (HPV), within Greater China market comprising of China, Hong Kong, Macao, and Taiwan. The agreement also provisions for potential inclusion of the Republic of Korea three years following the effective date. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/. One of Inovio Pharma's competitors within the Biotechnology space, Bio-Techne Corp. (NASDAQ: TECH), reported on February 07, 2017, its financial results Q2 ended December 31, 2016. AWS will be initiating a research report on Bio-Techne in the coming days. Today, AWS is promoting its blog coverage on INO; touching on TECH. Get all of our free blog coverage and more by clicking on the links below: http://www.activewallst.com/register/. As per terms of the agreement, Inovio will receive $15 million in upfront and near-term payments comprising an initial $3 million signing fee and a $12 million milestone upon lifting of the VGX-3100 phase-3 pre-initiation clinical hold by the FDA since October 2016. ApolloBio will fund all clinical development costs within the licensed territory, and will pay Inovio up to $20 million based upon the achievement of certain regulatory milestones in the US, China, and Korea, and double digit royalties on net sales of VGX-3100. Under a separate equity agreement, ApolloBio will invest in Inovio's common stock, once the hold on clinical trial is lifted at a volume weighted average price encompassing a trading period prior to and following the lifting of the clinical hold. Inovio stated that the investment will not exceed $35 million and is structured in a way that the amount may be lowered in order to ensure that ApolloBio will not be the largest shareholder in Inovio. The agreements are subject to People's Republic of China (PRC) corporate and regulatory approvals and payments are subject to PRC's currency approvals. This collaboration on VGX-3100 encompasses the treatment and/or prevention of pre-cancerous HPV infections and HPV-driven dysplasias, and excludes HPV-driven cancers and all combinations of VGX-3100 with other immunostimulants. Dr. J. Joseph Kim, Inovio's President and Chief Executive Officer, said: "As Inovio continues to focus on the path to regulatory approvals and commercialization strategies in the US and European countries, this agreement opens up Greater China for our lead program and first phase-III product. We believe that ApolloBio is a strong partner that brings significant capabilities and expertise relating to product development, the Chinese regulatory landscape, and the healthcare market in China." Inovio's VGX-3100 is an HPV-specific immunotherapy that is being developed as a non-surgical treatment for high-grade cervical dysplasia and related underlying persistent HPV infection. VGX-3100 works in vivo to activate functional, antigen-specific, CD-8 T-cells to clear persistent HPV 16/18 infection and cause regression of pre-cancerous cervical dysplasia. In a phase-II trial, VGX-3100 demonstrated clinical efficacy and was generally well tolerated, without the side effects and obstetric risks associated with surgical excision. VGX-3100 is a first-in-class HPV-specific immunotherapy that targets the underlying cause of cervical dysplasia, providing an opportunity for women to reduce their risk of cervical cancer without undergoing an invasive surgical procedure. As per the official press release, HPV is the most common sexually transmitted infection and is the main cause of cervical cancer, which kills more than 250,000 women every year worldwide. Among the 300 million women currently infected with HPV, 500,000 will be diagnosed with cervical cancer each year. Two types of HPV (HPV 16 and HPV 18) cause 70% of cervical cancer cases. High-grade cervical dysplasia is also caused by persistent HPV infection and is a pre-cancerous condition that can progress to cervical cancer if left untreated. Globally, the number of high-grade cervical dysplasia cases is estimated to be in the range of 10 million. Inovio stated that there are currently no approved medical treatments for persistent HPV infection or cervical dysplasia. The primary treatment for high-grade cervical dysplasia is surgical excision of the pre-cancerous lesion and a margin of healthy cervical tissue. At the close of trading session on Monday, February 13, following the announcement, Inovio Pharma's stock price jumped 6.57% to end the day at $6.81. A total volume of 1.46 million shares were exchanged during the session, which was above the 3-month average volume of 895.38 thousand shares. The Company's share price has gained 8.61% in the past twelve months. The stock currently has a market cap of $513.07 million. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Loading Bio-Techne collaborators
Loading Bio-Techne collaborators